Stocks
Phio Pharmaceuticals Corp.PHIO
NASDAQHealthcareBiotechnology$0.87
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics, primarily for oncology indications. Its lead candidate, PHIO-101, targets solid tumors and has shown early promise in clinical trials. Investors track the stock for its potential in the RNAi space and its ongoing clinical milestones.
52W Range: $0.81-$4.19
Congressional Interest in Phio Pharmaceuticals Corp. (PHIO)
No congressional trades have been disclosed for Phio Pharmaceuticals Corp. (PHIO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading PHIO?
No congressional trades found for this stock.